Goldman Sachs initiated coverage of Sanofi (SNY) with a Neutral rating and $65 price target While the firm sees Sanofi emerging as a pipeline ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price target ...

Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune ...

Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

The aim is to prepare for the onset of biosimilar competition in the 2030s to Sanofi’s current immunology blockbuster Dupixent (dupilumab), which is predicted to top $14 billion in sales this ...

What do you think? By Michael Gonchar Weekly Student News Quiz: Education Department, March Madness, Deadly Storms Have you been paying attention to current events recently? See how many of ...

The New York Rangers unveiled their Centennial Year logo that will be featured throughout the 2025-26 season. The logo ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Stay updated on market trends for TEVA. Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease Teva and Sanofi's duvakitug ...

After hours: March 25 at 6:19:29 PM EDT Loading Chart for SNY ...